Abstract
The goal of our study was to prepare carboplatin niosomes for enhanced delivery to cancer cells by thin film hydration technique using (cholesterol: surfactant) in the micromolar ratio of 30:100 and with/without the addition of charge inducing agents and Pluronic F 68. Photomicrographs of the formulations show the presence of multilamellar vesicles in the forumulation with Tween 80 and Pluronic F 68. The vesicle size of the formulation was found to be in the size range of 0.01-1µm. Carboplatin niosome formulation without any charge inducing agent and Pluronic F68 shows good drug entrapment (89.24%) with an in vitro release of 87.23% in 12 hours. Drug release kinetics of the formulation follows the Non Fickian diffusion mechanism and exhibits first order release kinetics. The in vitro cytotoxicity results of the formulations reveal that the Tween 80 formulation with Pluronic shows the highest level of cytotoxicity (90%) when compared with drug in solution. Also, the stability studies of the formulations reveal that the formulations were stable in refrigerated condition.
Keywords: Carboplatin, Cancer and Niosomes, in vitro Cytotoxicity, Drug targeting, therapeutic, immunoglobulins, serum proteins, synthetic polymers, liposomes, microspheres, erythrocytes, phospholipid, nonionic surfactant, viruses.
Drug Delivery Letters
Title:Formulation and Evaluation of in vitro Cytotoxicity of Carboplatin Niosomes
Volume: 2 Issue: 3
Author(s): V. Sankar, I. R. Antony Noby, B. Ramakrishna, Elizabeth Babu, Shalini Devi Penmetsa and Sivaram Hariharan
Affiliation:
Keywords: Carboplatin, Cancer and Niosomes, in vitro Cytotoxicity, Drug targeting, therapeutic, immunoglobulins, serum proteins, synthetic polymers, liposomes, microspheres, erythrocytes, phospholipid, nonionic surfactant, viruses.
Abstract: The goal of our study was to prepare carboplatin niosomes for enhanced delivery to cancer cells by thin film hydration technique using (cholesterol: surfactant) in the micromolar ratio of 30:100 and with/without the addition of charge inducing agents and Pluronic F 68. Photomicrographs of the formulations show the presence of multilamellar vesicles in the forumulation with Tween 80 and Pluronic F 68. The vesicle size of the formulation was found to be in the size range of 0.01-1µm. Carboplatin niosome formulation without any charge inducing agent and Pluronic F68 shows good drug entrapment (89.24%) with an in vitro release of 87.23% in 12 hours. Drug release kinetics of the formulation follows the Non Fickian diffusion mechanism and exhibits first order release kinetics. The in vitro cytotoxicity results of the formulations reveal that the Tween 80 formulation with Pluronic shows the highest level of cytotoxicity (90%) when compared with drug in solution. Also, the stability studies of the formulations reveal that the formulations were stable in refrigerated condition.
Export Options
About this article
Cite this article as:
Sankar V., R. Antony Noby I., Ramakrishna B., Babu Elizabeth, Devi Penmetsa Shalini and Hariharan Sivaram, Formulation and Evaluation of in vitro Cytotoxicity of Carboplatin Niosomes, Drug Delivery Letters 2012; 2 (3) . https://dx.doi.org/10.2174/2210304x11202030223
DOI https://dx.doi.org/10.2174/2210304x11202030223 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Clinical Aspects of Tumor Necrosis Factor-α Signaling in Hepatocellular Carcinoma
Current Pharmaceutical Design <sup>109</sup>Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy
Current Radiopharmaceuticals Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Structural and Mechanistic Insights of CRAC Channel as a Drug Target in Autoimmune Disorder
Current Drug Targets